StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

Gene editing therapy companies experienced a surge in stock prices over the past week, with many shares jumping by double digits. The two primary growth factors behind this positive trend were the European Society of Gene and Cell Therapy’s 33rd ESGCT Annual Congress and the FDA's issuance of draft guidance on personalized gene therapies for rare genetic diseases.

The ESGCT Congress, held in Hamburg, Germany, provided a platform for developers of new editing-based therapies to share positive data readouts. Meanwhile, the FDA's draft guidance, Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management, introduced the concept of the Individualized Feature Space (IFS), which outlines allowable limits of variation for genome edited components in individualized gene therapies.

This regulatory framework aims to de-risk data and regulatory efforts for these therapies, allowing them to vary from patient to patient without requiring additional clinical trials. The FDA is currently accepting public comments on the draft guidance until November 27.

Since the guidance was issued after market close, investors had to wait until Wednesday to assess the impact of the proposed rules combined with ESGCT data on gene editing stocks. The most significant gains this week belonged to Prime Medicine (PRME), whose shares jumped 29% from $3.67 to $4.72. Prime Medicine's stock soared as a result of FDA clearance for a planned Phase I/II trial of its in vivo Prime Editor PM647 for alpha-1 antitrypsin deficiency (AATD) and the dosing of the first patient in a Phase I/II open-label trial for its PM577a in adults and teens with H1069Q-mutated Wilson disease.

Beam Therapeutics (BEAM) also experienced a significant rise, with shares climbing 13% from $24.05 to $27.23. This increase was largely driven by positive initial data from Beam's Phase I/II trial (NCT06735755) showing clinical proof of concept for BEAM-301, a liver-targeting lipid-nanoparticle formulation of base editing reagents designed to correct the R83C mutation in the most severe form of glycogen storage disease type Ia (GSDIa).

Beam Therapeutics' maximum potential sales estimates for BEAM-301 are nearly $475 million, representing a 31% increase over the $362 million peak sales projection for Genglycos, an FDA-approved drug for GSDIa that was marketed by Ultragenyx Pharmaceutical (RARE).